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Context. Hadrontherapy is an innovative form of radiotherapy using beams of protons or carbon ions able to destroy some radio-
resistant tumours. Because these tumours are highly specific amongst all cancerous tumours, it is impossible to determine the
incidence of these diseases from surveillance registries. Goal. To assess, within the Rhoˆne-Alpes region, the incidence of cancers
being hadrontherapy indications. Method. Prospective, multicentre continuous data collection during 1 year, by practitioners
participating tomultidisciplinary tumor board. Tumours are inoperable, radio resistant, at primary stage of development, or locally
recurrent, with low metastatic potential. Results. Study involved 27 healthcare centres, 52 groups of specialist practitioners. The
estimated incidence of cancers eligible for hadrontherapy in the Rhoˆne-Alpes region in 2010, that is, for 34 locations in all, is of
8.5/100 000 inhabitants. Appraisal of the low potential of metastatic progression is impeded, because these are rare diseases, whose
outcome is unfamiliar to investigators. Conclusion. Future epidemiological studies will need to focus on prognosis and on the
metastatic progression rate of these diseases. Indeed, there are few information available on this subject in the literature that could
be used to improve preventive measures, medical care, and the surveillance of these rare cancers.
1. Scientific Context
1.1. Hadrontherapy. Hadrontherapy is an innovative form of
radiotherapy, based on high-technology equipment using
proton or carbon ions beams to destroy tumours [1, 2].
This treatment method enables significantly higher ballistic
precision to be achieved, compared to photons (X-rays)
with, as expected therapeutic benefit, an improvement of
quality of life and chances of recovery [3]. Carbon ions are
also specifically characterised by superior biological efficacy
(relative biological effectiveness from 1.5 to 3), overcoming
the radiation resistance of certain cancers to photons and
even protons. Indeed, carbon ion beams when compared to
X-rays represent a distinct advantage for the treatment of
highly radiation-resistant tumours [4].
1.2. Hadrontherapy Epidemiological Studies. An initial study
assessing recruitment potential for proton therapy was con-
ducted in 1998 in Italy, showing an incidence of 10 825
cases/year [5]. One year later, a second study was carried out
in the context of theMedAustron project for the construction
of a carbon ions therapy centre in Austria. Considering
patients living in Austria and neighbouring countries, the
patient recruitment potential (proton and carbon) was esti-
mated with an incidence of 13 145 cases/year [6]. In France,
in 2002, a third study was conducted in the context of
the ETOILE medical project. This study revealed an annual
incidence of approximately 5320 cases/year for carbon ions
[7]. Concomitantly, a fourth study was conducted, again
in the context of the MedAustron project, estimating the
incidence of cases eligible for hadrontherapy in Austria at
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(1) Selection of all items to study. Each item is a couple of indication and
treatment (example: cancer of cavum- treatment by radiochemotherapy).
Relevant clinical outcomes and duration of followup were also defined.
(2) Exhaustive literature research for each item.
(i) First selection based on the title and the abstract. 
(3) Selection of trials.
(ii) Second selection and after a full paper reading.
(4) Description of each selected trial.
(i) Description of patient characteristics, treatments, and toxicities.
(ii) Results on efficacy.
(5) Synthesis of efficacy results.
(6) Drafting of final reports.
(i) Methodology of research.
(ii) A synopsis by item.
(iii) Detailed tables with all included studies.
(iv) References of included studies.
Definition and validation of the
items
(2 or 3 French physicians + 1 European)
1 item = a specific indication
+ a given treatment
Drafting of protocol
Professor Jean-Pierre Boissel team
Research of the studies
Strategy: (i) design of the study
(ii) studied pathology
(iii) tested treatments
Sources: (i) Medline, Cochrane library
(iii) others websites (on going studies)
Bibliographic database managed with reference manager
Selection of the studies
1st step: abstracts
(randomized controlled trials > controlled trials
noncontrolled observational trials)
Extraction of the data
Professor Jean-Pierre Boissel team
Identification and indexation
Description of treatments, outcomes, patient, and
experimental design
Synthesis of information
drafting of final reports
Professor Jean-Pierre Boissel team
1 synopsis per item
1 final report per particular type of tumours
Professor Jean-Pierre Boissel team ∗
Professor Jean-Pierre Boissel team
2nd step: full text then publication type and methodology
(ii) institutions “websites and recommendations”
∗ Professor Jean Pierre Boissel, center of data treatment, UMR 5558, 
Medicine University of Laennec, Lyon, France
Figure 1: Literature review method.
2044 cases/year [8]. Finally, again in 2002, in the context
of the project for the construction of the CNAO centre in
Italy, an epidemiological study was conducted, estimating
the incidence of cases eligible for carbon therapy at 3694
cases/year and proton therapy at 1885 cases/year. [9]. Since
2004, no other epidemiological studies have been published
for hadrontherapy.
In 2011, however, the Japanese team from the National
Institute for Radiological Sciences (NIRS), pioneer in carbon
therapy, published the results of its 1994 to 2011 clinical
activity. Patients were included in clinical trials and the
number of patients receiving carbon therapy was 6157 [10].
This value is the incidence of treated cases, over 17 years
without any notion of recruitment potential and with a rather
slow ramp up of the activity.
1.3. Therapeutic Indications for Hadrontherapy. A list of pri-
ority indications that can be treated by hadrontherapy
(Table 1) was drawn up by the GCS ETOILE medical group,
in collaboration with national and international experts,
based on published data ranked using an “evidence-based
medicine” type analysis (Figure 1). This literature review
was based on provided or expected medical service criteria
(survival and quality of life). According to the classification
used by the European Survey Group of Rare Diseases [11],
the eligible tumours that can be treated by hadrontherapy
conform to the criteria of rare diseases based on the fol-
lowing thresholds of epidemiological indicators: prevalence
≤ 50 cases/100 000 persons within a given population and
incidence ≤ 6 cases/100 000 persons/year. Indeed, for all
tumor types identified during the previous hadrontherapy
epidemiological studies [5–8], the calculated and cumulative
incidences are all below these thresholds (Table 2). Amongst
the hadrontherapy indications, 25 are tumours listed in the
ORPHANET international database of rare diseases [12] (cf.
ORPHANET number in Table 1).
1.4. Problem. The exact incidence of each disease eligible for
hadrontherapy is difficult to determine from the available
resources. Indeed, the published data [5–13] pertain to series
of patients for which the aim was not to assess the level of
demand for treatment. These were rather series of patients
who had received the therapy, but whose recruitment had
not been accounted for in tumour registries. Considering
the scarcity and specific nature of the tumours concerned
by hadrontherapy, it is difficult to extrapolate and assess
the treatment demand from these results. Hadrontherapy
indications are defined according to anatomical location of
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Table 2: Results, EpiHadron study: summary of incidence rates calculated during hadrontherapy epidemiological studies conducted between
1998 and 2004.
Country Grossincidence/year∗
Incidence/
/100,000
inhabitants/year∗
Total population
during the year of the
study (u`)
Study year Related healthcarecentre
Italy 10,825 19 56 908 265 1998 CNAO
Austria 4873 61 7 982 461 1999 Med-AUSTRON
Switzerland 263 4 7 123 537 1999 Med-AUSTRON
Slovenia (a) 626 31 2 000 092 1999 Med-AUSTRON
Hungary 153 1 10 253 400 1999 Med-AUSTRON
Italy 313 1 56 913 634 1999 Med-AUSTRON
Czech Republic (b) 5060 50 10 190 000 1999 Med-AUSTRON
Slovakia (y) 1734 32 5 477 038 1999 Med-AUSTRON
France 5320 9 61 424 036 2002 ETOILE
Austria 2044 25 8 063 640 2002 Med-AUSTRON
Italy 5579 10 57 888 245 2004 CNAO
∗Estimate expressed in study population, irrespective of disease location.
(y, a, b) Estimate of 2011, no data available before this date.
(u`) Demographic sources.
http://www.statistiques-mondiales.com.
http://appsso.eurostat.ec.europa.eu/nui/setupModifyTableLayout.do.
http://www.diplomatie.gouv.fr.
the tumours, clinical stage, pathology, therapeutic alterna-
tives (e.g., surgical contraindications), and patient character-
istics (general condition and comorbidities). French cancer
registries record data required to estimate cancer incidence
but fail to provide sufficient detail of the tumour stage
or of therapeutic data. Moreover, the registries cover only
approximately 15% of the French population and mainly for
the most frequent cancers. Therefore, these registries do not
allow the incidence of these tumours to be estimated.
1.5. Challenges and Prospects. This regional study will pro-
vide us with more detailed figures concerning the potential
number of new cases eligible for hadrontherapy, allowing us
to better adapt the future care offer delivered by the national
hadrontherapy centre. This survey should also provide us
with information on certain medical indicators to assist in
the design of future hadrontherapy clinical trials (detailed
incidence data, patient population characteristics, tumour
stages, recruitment pools, etc.). Finally, this epidemiological
field study is also eventually intended to be used to organise
a network of highly specialised cares.
1.6. Hypothesis. According to the first epidemiological study
carried out in France [6], in association with (i) the results
of the literature review that defined the list of hadrontherapy
indications and (ii) the indications chosen for proton therapy
in France, the number of cases in the Rhoˆne-Alpes region
eligible for hadrontherapy is estimated at 200 per year
(the Rhoˆne-Alpes region is home to 10% of the French
population).
2. Goals
Themain goal is to asses, within the Rhoˆne-Alpes region, the
incidence of cancers with hadrontherapy indication.
The secondary goals are (1) to characterise the affected
population, (2) to describe the characteristics of the observed
cancers, and (3) to describe the characteristics of the treat-
ments implemented when hadrontherapy is unavailable.
3. Method
Study Outline. This is a prospective, multicentre incidence
study, lasting 24 months, conducted with the RCP (Re´union
de Concertation Pluridisciplinaire—multidisciplinary tumor
board) groups of the Rhoˆne-Alpes region in France, that offer
a therapeutic strategy for cancers for which hadrontherapy is
an alternative.
Centre Recruitment and InclusionMethod.This study required
the involvement of a part-time consultant epidemiology
engineer, who totalled one woman-year of work to provide
(1) phone canvassing to identify and involve regional cancer
research players; (2) the protocol construction and testing
phase, along with the data collection tools; (3) meetings with
3C (cancer coordination centres) coordinators and RCPs; (4)
investigator centres inclusionmeetings. An extensive number
of travels within the region were required for these tasks.
Variables Collected. These included year of birth; gender;
patient’s department of residence; World Health Organiza-
tion (WHO) performance status, patient’s therapeutic status:
initial stage or recurrence; initial staging (UICC TNM clas-
sification: International Union against Cancer); treatments
received before recurrence; time to recurrence; staging at
time of current tumour management; ICD-10 (International
Classification of Diseases); ICDO (International Classifica-
tion of Diseases for Oncology) histological type; site of
surgery and margin quality; postsurgical histopathological
stage (pTNM stage); prior radiotherapy; proposed treatment.
6 Journal of Cancer Epidemiology
“Patient” Inclusion Criteria. The criteria included adults and
children, no age limit, and patients presenting with hadron-
therapy indications listed in Table 1, whose medical files have
been discussed by experts during an RCP. Subjects must be in
compatible general and psychological condition.
Definition of “Patient” Inclusion Criteria. Compatible general
and psychological condition refers to patients not suffering
from life-threatening comorbidities (no acute or chronic
diseases whose short-term lethal risk is dominant relative
to the cancer), capable of adhering to a disease monitoring
protocol and of understanding and accepting a complex
treatment requiring close cooperation and staying for several
days away from home.
“Tumour” Inclusion Criteria. These include unresectable
tumour, belonging to a known radiation-resistant patho-
logical group, mainly in a locoregional development stage,
recurrent or local relapse, with low metastatic potential
or M+ dissemination (presence of one or more remote
metastases at the time of diagnosis) presenting a low threat
(slow development and/or metastases that can be readily
treated).These inclusion criteria are the results of a consensus
synthesis of a systematic literature review performed during 8
years, pathology by pathology with the participation of about
one hundred of European medical, surgical, and radiation
oncologists, managed by physicians trained in hadrontherapy
(mainly protontherapy). The review was carried out by an
academic laboratory specialized in clinical trial setup and
analysis and was made according to the “evidence-based
medicine” principle.
Definition of “Tumour” Inclusion Criteria
(i) Radiation resistance: tumour which estimated local
dose required for local control that is higher that
the maximum acceptable dose equivalent (MPDE)
for surrounding organs necessarily irradiated under
applicable technical conditions, assessed by a radi-
ation oncologist (guide des Proce´dures de Radio-
the´rapie Externe 2007 (guidelines for external radio-
therapy procedures); joint effort by the French soci-
ety for oncology radiotherapy (socie´te´ Franc¸aise de
radiothe´rapie oncologique—SFRO), and the French
society for medical physics (socie´te´ franc¸aise de
physique me´dicale—SFPM), conducted in collabora-
tionwith the representatives of the French association
of electroradiology paramedical workers (association
franc¸aise du personnel parame´dical d’electroradiolo-
gie—AFPPE)).
(ii) Unresectable: tumour which local or locoregional
expansion stage renders excision either is technically
impossible (opinion of an experienced surgical team)
or surgically unacceptable due to the irreparable
damage that would be necessary (cancer: Principles &
Practice ofOncology 2005; DeVita, V. General articles
on treatment strategies in cancer).
(iii) Locoregional: it refers to the tumour expansion state
corresponding to the anatomical diffusion region of
the primary tumour by contiguous expansion (T of
TNM) and/or by lymphatic diffusion, maintaining
a rank of N in TNM staging, in other words, any
tumour at stage M0 (latest edition of the tumour
TNM classification published by the (UICC) Interna-
tional Union against Cancer or the (AJC) American
joint committee for cancer staging).
(iv) Low metastatic potential: M0 situations whose
medium-term (5-year) metastatic risk is considered
to be sufficiently low to justify curative locoregional
treatment involving significant means.This threshold
is difficult to determine; a level greater than 50%
seems unreasonable. As an example, mucosal
melanomas are just at this threshold.
(v) Nonthreatening M+ dissemination or controlled by
medical treatments: this means the presence of one
or more remote metastases at the time of diagnosis,
presenting no immediate threat as displaying slow
development and/or accessible to effective treatment
(typical case of some low-grade sarcomas lungmetas-
tases). These situations are indicative of locoregional
disease treatment using complex and expensive tech-
niques such as hadrontherapy.
(vi) Local relapse or local recurrence (these two terms
are synonymous): it means the redevelopment, at
the same site as initially, of a previously effec-
tively treated tumour (dictionary of medical terms,
Garnier-Delamare).
Primary Endpoint. it is the quantitative estimate of the
incidence of indications eligible for hadrontherapy.
Secondary Endpoints.They are the description of the tumours
and population characteristics, along with the treatments
proposed and implemented by the RCPs.
Types of Investigation Centres and Participant. Those were
healthcare establishments (private and public) in the Rhoˆne-
Alpes region hosting RCP groups and having radiotherapy
departments.
Types of RCPGroups Participating in Screening. they consisted
of groups of oncology specialists with expertise in the
following diseases: musculoskeletal sarcomas and tumours,
Head and Neck (H and N), gastroenterology, paediatrics,
dermatology, endocrine and central nervous system tumours.
Case Screening Modalities. Case screening is performed con-
tinuously by the physicians and clinical research technician
in light of the list of indications (Table 1), during each RCP.
Data Collection Modalities. Data are collected in a decen-
tralised prospective manner on paper questionnaires.
Study Monitoring. Fifteen percent of files were checked to
ascertain data accuracy.
Study Quality.Thequestionnaire, along with the organisation
of the investigation, was assessed beforehand by a sample
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population of investigators (3C coordinators and CRAs) via
a semiguided telephone interview. For the questionnaire, the
evaluation focused on general understanding, the form and
length of the questionnaire, time required for completion,
amount of data to collect, and the relevance of the selected
criteria.The evaluation of the investigationmethod pertained
to the choice of individuals involved in data collection
organisation, the data recordingmethod, the organisation for
data recording, and the identification source for clinical cases.
Data Quality. Variables are encoded in a uniform and
standard manner in an investigator’s guide book, which
contains detailed information concerning the definitions
of each indicator to collect. Dual computer data input is
performed, along with checks for missing or improbable data
(encoding errors, date inconsistencies).
Statistical Methods. No sampling is performed as this study
is intended to be exhaustive. The incidence of cancers is
expressed as the number of cases reported from the demo-
graphic figures of the Rhoˆne-Alpes region over the studied
period and expressed per 100,000 inhabitants. Estimations of
endpoint descriptive characteristics are expressed as frequen-
cies, means, and percentages. Analyses are performed using
Microsoft Excel, version 2008.
4. Results
The study involves 13 clinical research technicians, 50 RCP
coordinating physicians and 12 cancer coordination centres
(see Table 3). The study mobilises 27 Rhoˆne-Alpes region
healthcare centres, of which 8 university hospitals, 1 regional
cancer centre, 1 public-private cancer institute, 12 general
hospitals, the Lyon paediatric oncology hospital institute, and
4 private clinics. The study test phase validated the tools
and organisation of this investigation. This led to a sense
of ownership and motivation on the part of the centres.
As a whole, the study covered the region’s 11 hospital areas
and involved 52 groups, out of some sixty listed, of cancer
specialists with expertise in the diseases that were to identify.
During the study, 53 cases eligible for hadrontherapywere
identified. Mean patient age was 43 years [2–89], and men
were more numerous (OR = 1.52). The highest number of
cases (39.6%) was in the 2–18 years age group. The number
of patients with recurrence was slightly lower (45.3%) than
the number of patients receiving initial care (54.7%). Carci-
nomas, sarcomas (Table 4), and paediatric tumours (Table 5)
were the most frequently identified diseases, and their loca-
tions are varied. During the RCP, radiotherapy, chemother-
apy, and surgery were prescribed, respectively, in 58%, 57%,
and 57% of cases. No brachytherapy was prescribed.
For the group of 45.3% relapsing patients, previous treat-
ments were chemotherapy, surgery, or conventional radio-
therapy in 62.5%, 58.3%, and 58.3% of cases, respectively.
The number of cases identified during the study was
approximately four times lower than the potential estimate.
(Figure 2) Data collection was nonhomogeneous. The Ise`re
department identified 43.4%of cases (i.e., 2.5 cases/RCP), and
the Rhoˆne department identified 56.6% (i.e., 1.2 cases/RCP).
Ise`re identified twice as many cases as Rhoˆne, even though
it only has nine expert groups, that is, 2.6 times less than in
Rhoˆne, which has 24. The geographic areas not covered by
the study correspond to the location of 15 private healthcare
centres and to the medical activity of six general and four
specialist RCP groups.Thefirst six groups had no recruitment
potential according to the statement of their coordinators.
The four other groups had a recruitment potential.
This preliminary data collection, conducted over a one-
year period, reported 53 cases of hadrontherapy indications,
compared to the estimated cap of 200 cases.TheRhoˆne-Alpes
region was home to 6,222,045 inhabitants in 2010 [14]. The
estimated incidence of cancers eligible for hadrontherapy in
the Rhoˆne-Alpes region in 2010, regardless of disease, is of
8.5/100,000 inhabitants.
5. Discussion
5.1. About the Method. The diseases to identify in this study
are little known, their distribution has not been studied,
and we are unaware of any epidemic outbreaks. Moreover,
considering that the cancers to identify are rare, it is likely that
the number of cases to identify per investigator centre will be
very low (estimated incidence of at themost 1 to 5 cases/year).
Finally, the primary goal of the RCP groups is to provide
an immediate therapeutic solution. Case identification for an
observational study is thus unusual in the context of an RCP.
Because of this, sustaining team vigilance and motivation for
case identification is difficult to obtain and requires regular
refreshing throughout the study.
The study test phase validated the tools and organisation
chosen for this investigation.This step also served to circulate
hadrontherapy information and to facilitate adhesion, own-
ership, and mobilisation around the project. The individuals
involved in study organisation were in charge of systemat-
ically directing each cancer patient to the elective experts.
Patients suffering from diseases eligible for hadrontherapy
were frequently in relapse condition and rather at the end of
their therapeutic options. This is due to the fact that these
diseases have usually a slow and long evolution; therefore,
this study had more chance to catch them somewhere in
an advanced stage than at the beginning. It can also be
considered that the lack of satisfactory treatment means as
hadrontherapymakes these populations have more chance to
show more advanced disease than it will be expected to be
seen in the future. Their management requires discussion by
a medical team of cancer specialists. The identification and
decision to include a patient in the study were made by the
RCP groups including these experts. Under these conditions,
we have confidence in the case orientation and identification
system.
The “tumour with low metastatic development potential”
selection criterion is one of the criteria used to identify
patients eligible for hadrontherapy. In our current state
of knowledge, however, this indicator gives clinicians the
greatest difficulties.
The results of this study were obtained mainly from
public hospitals. This can be explained in part by the fact
that it is easier to create multidisciplinary expert groups
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Table 3: Results, EpiHadron study: organisation, patient, and tumour characteristics.
Categories Population sizes (𝑛) %
Organisations
Investigating establishments 27 —
RCP groups: multidisciplinary consultation meeting 52 —
Cancer coordination centres 12 —
RCP coordinating physicians 50 —
Clinical research associate 13 —
Patient characteristics
Patient age (mean) 43 years [2–89] —
Man 32 60.4
Woman 21 39.6
Initial care 29 54.7
Recurrent cancer 24 45.3
Tumour characteristics
Mean tumour size (largest circumference) 69mm [19–250] —
Metastases present 11 20.8
Lymph nodes present 10 18.9
Identified Cases
In total (𝑁) 53 —
By age group
[2–18] years 21 39.6
[18–45] years 0 0
[45–65] years 18 34
[65–69] years 0 0
[69–89] years 14 26.4
By RCP type
Head and neck H and N 4 7.5
Digestive 12 22.6
Sarcoma and soft tissue 2 3.8
Central nervous system CNS 2 3.8
Paediatrics 21 39.6
Dermatology 4 7.5
General practice 6 11.3
Oncology 1 1.9
Other 1 1.9
in public hospitals and to set up clinical research. Due to
their structure, these establishments benefit from human
resources with more varied medical specialities than in
private radiotherapy practices. In all likelihood, cases eligible
for hadrontherapy could have been treated by these private
centres during the study and ignored.
One should be very cautious when comparing the results
of this study with those of published incidence studies. The
methodologies employed in these previous studies are het-
erogeneous, and/or their flow is insufficiently documented.
Moreover, their goal was to estimate a recruitment potential
based on the extrapolation of the results. The methodologies
usedwere not intended to provide information concerning an
exhaustive incidence, as proposed by our study. Finally, the
published studies were conducted in attractive institutions,
specialising in cancer care and selected for this reason;
this may bias the assessment of prevalence. Under these
conditions, it is easy to confuse incidence and prevalence. It
is thus conceivable that the estimation of incidence in the
literature is overestimated. These elements could, in part,
explain the observed difference between the preliminary
results obtained in our study and the estimate calculated from
the epidemiological results published in the literature. Only
the publication of results obtained from other exhaustive
epidemiological studies conducted in the same areas could
support this hypothesis.
5.2. About the Results. It is unlikely that the lack of case
recording associated with the medical activity of the four
groups not involved in this data collection could alone explain
the observed difference between the calculated incidence
estimates and the preliminary results obtained. For several
clinicians involved in the study, the prognosis and risk of
metastatic development were difficult to estimate considering
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Table 4: Results, EpiHadron study: list of cases identified by anatomical type.
Type Category Location Population sizes (𝑛) % C/P
Carcinomas
Adenocarcinoma
of the endometrium 1 1.9 C
of the pancreas 1 1.9 C
of the rectum 7 13.2 C
caecum with invasion of the psoas 1 1.9 C
Cystic glandular of the left parotid gland 1 1.9 C
of the arytenoid cartilage 1 1.9 C
Epidermoid
of the scalp 1 1.9 P
oesophagus 2 3.8 P
retromolar or intermaxillary commissure 1 1.9 P
oropharynx 1 1.9 P
Other
basal cell 1 1.9 C
of the rectum 1 2.3 C
neuroendocrine pancreatic 1 1.9 C
Total
carcinomas
20 38.2
Sarcomas
Osteosarcoma
of the humerus, upper end 1 1.9 C
thigh and leg bone or cartilage 1 1.9 C
osteogenic of the calvarium 1 1.9 C
Leiomyosarcoma of the mucosal maxillary sinus 1 1.9 C
Chondrosarcoma of the larynx 1 1.9 P/C
Skin posterior basicervical 1 1.9 C
Liposarcoma 1 1.9 C
Ewing’s 5 9.4 P/C
Rhabdoı¨d clival 3 5.7 C
Grade II myxofibrosarcoma antero-external part of the left leg 1 1.9 C
Total sarcomas 16 30.2
Skull Brain and
Spinal
column
Neuroblastoma of the base of the skull 1 1.9 P
Glioma
of the brain stem nuclei 1 1.9 P/C
of the optic nerve 1 1.9 P
hypothalamic-chiasmatic 1 1.9 P
Glioblastoma 3 5.7 C
Grade IV medulloblastoma of the posterior cerebral fossa 2 3.8 P
Craniopharyngioma 1 1.9 C
Malignant melanoma of the left maxillary sinus 1 1.9 C
Xanthoastrocytoma of the temporal lobe 1 1.9 P/C
Total brain 12 22.6
Other
Merkel cell tumour of the left buttock 1 1.9 C
Chordoma sacrum 2 3.8 C
Adrenal tumours 2 3.8 C
Total other 5 9.4
Totals (𝑁) 53 100
Legendary: C: carbon, P: proton.
the lack of knowledge for these rare diseases. Moreover, the
novelty of hadrontherapy, which can potentiallymodify usual
treatment strategies, could have led to the omission of this
indication in some cases, in particular conditions unusually
treated by radiotherapy as hepatic and biliary tumours.These
difficulties, along with the more sustained vigilance effort
made by some groups relative to others, could account
for the nonhomogeneous data collection and the observed
difference between predictions and obtained results, despite
the high motivation of the investigators. Furthermore, the
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Table 5: Results, EpiHadron: list of cases identified by anatomical type for paediatric tumours.
Paediatric tumours Category Location Population sizes (𝑛) %
Neurological tumours
Neuroblastoma The base of the skull 1 4.8
Neuroblastoma Right adrenal gland 1 4.8
Neuroblastoma The adrenal glands 1 4.8
Grade IV medulloblastoma The posterior cerebral fossa 2 9.5
Glioma The brain stem lymph nodes 1 4.8
Glioma The optic nerve 1 4.8
Glioma Hypothalamic-chiasmatic 1 4.8
Craniopharyngioma 1 4.8
Sarcomas
Osteosarcoma Thigh and leg bone and cartilage 1 4.8
Osteosarcoma Upper end of the humerus 1 4.8
Osteogenic Osteosarcoma The calvarium 1 4.8
Ewing’s sarcoma 5 23.8
Rhabdoid sarcoma 1 4.8
Xanthoastrocytoma Temporal neurological 1 4.8
Rhabdoid tumour The clival region 2 9.5
Total paediatric tumours 21 100
EpiHadron results
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Figure 2: Results, EpiHadron study: number of cases identified relative to the number of groups involved in each department.
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reorganisations (case of two major RCP clusters), changes of
persons involved and the low frequency of cases to report,
lead to a constant erosion of vigilance, requiring continuous
action by the organiser.
This work aimed to structure a network of care pathway.
However, some important institutionswith their own recruit-
ment targets did not wish to participate, which reduces the
scope of our results.
About the detailed conditions of the recruited cases, there
are a large proportion of recurrent diseases as explained
above, and some metastatic diseases have also been included
according to defined characteristics: (i) the number of metas-
tasis was limited (1 to 3 metastasis); (ii) their very slow
growing speed was not immediately threatening; (iii) the
possibility of effective treatment of these “pauci-metastatic”
conditions, essentially by ablative procedures. Actually, the
principle to treat, with curative intend, patients in such
situation is more and more accepted by expert oncologists.
The estimated incidence of cancers, irrespective of type
and location, eligible for treatment by hadrontherapy, for the
study, that is, 8.5/100,000 individuals, is mildly higher than
the reference incidence threshold of ≤6 cases/100,000 indi-
viduals, as defined in the ORPHANET international database
of “rare diseases” [12]. This figure can be obviously explained
by the fact that the incidence was calculated by adding the
five major cancer categories and 34 different locations. If one
was to calculate the incidence for each of the disease types,
their respective incidence would be significantly below the
reference threshold of≤6 cases/100,000. Indeed, for our study,
the minimum number of cases listed per disease is of 1 case
and the maximum is of 7 cases. Table 4.
Considering all of the difficulties and limitations of this
preliminary phase of the study, the yield of approximately
25% notification, compared to the expected maximum,
appears satisfactory. In the perspective of a (necessary) ramp
up of a future hadrontherapy centre, there is thus a sufficient
population to initiate operation and to progressively establish
recruitment for this centre, without immediately generating
an insufficient offer effect.
6. Conclusion
Future epidemiological studies will benefit from focusing on
the characterisation of themetastatic development of diseases
eligible for hadrontherapy. All cancers have their own devel-
opment pattern, and, in this respect, the literature provides
few elements concerning diseases eligible for hadrontherapy.
This information should serve both to improve diagnosis
procedures, medical care, and the surveillance of these rare
diseases.
This study of hadrontherapy healthcare decision net-
works in the Rhoˆne-Alpes region, able to identify areas not
properly covered by RCPs, should enable us to analyse the
potential effect of this lack on the outcome of the patients of
these areas.
Incidence studies will be insufficient to determine the
actual impact of hadrontherapy activity. These studies
provide condensed elements about the medical activity
associated with new patients only. They shed no light on
posttreatment medical activity: follow-up visits, medical
imaging, and other care beyond the irradiated activity per se.
One of the most valuable outcomes of this study has
been to make the existence of some particularly rare diseases
known and to provide information concerning an innovative
treatment: hadrontherapy, whose existence will doubtless
have a favourable effect on the very knowledge of these
diseases. An additional benefit of this approach has been
to open the way for a new treatment system in a region of
France that is home to approximately 10% of the country’s
population. At last, these elective indications will have to be
validated by health authorities to register them as part of the
good professional practices of oncology and give an equal
chance to each patient to receive hadrontherapy through the
well-established decision process of the RCPs.
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